No Data
No Data
Express News | Innovent Announces Phase 2 Clinical Study of Picankibart (Ibi112) in Chinese Patients With Ulcerative Colitis Met Primary Endpoint
Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients With Ulcerative Colitis Met Primary Endpoint
SAN FRANCISCO and SUZHOU, China, Oct. 17, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and
The tenth batch of national procurement reporting documents have been leaked, industry insiders: does not represent the final list of centralized procurement varieties. The competition intensity will reach new heights.
①A document of the tenth batch of national procurement reporting catalog has circulated within the industry. Today, when the reporter verified with the relevant department, they indicated that it is an internal document not for public release, and the formal joint procurement document will be released publicly later. ②Several industry experts have provided feedback to the reporter, stating that this reporting catalog does not represent the final procurement catalog. However, the competitive landscape of the tenth batch of national procurement will involve at least seven companies. ③The competition for the tenth batch of national procurement will be exceptionally fierce.
Innovent Bio (01801.HK) received JPMorgan's shareholding of 10.1839 million shares.
According to the latest equity disclosure data from the Hong Kong Stock Exchange on October 15, 2024, innovent bio (01801.HK) received a shareholding of 10.1839 million shares at an average price of HK$48.0257 per share from JPMorgan Chase & Co. on October 8, 2024, involving approximately HK$0.489 billion. After the shareholding, JPMorgan Chase & Co.'s latest holding of good warehouses is 102,360,912 shares, and the proportion of good warehouses held has increased from 5.65% to 6.25%.
Hong Kong Stocks Fall on Uncertainty in Further Stimulus; Pharma Firms Lead Decline
[Brokerage Focus] Tianfeng maintains a 'buy' rating on Innovent Bio (01801), indicating that its research and development pipeline will enter a period of product harvesting.
Kin Wus financial news | tianfeng securities issued a research report, in the first half of 2024, innovent bio (01801) total revenue was 3.95 billion yuan, a year-on-year increase of 46.3%; product revenue was 3.81 billion yuan, a year-on-year increase of 55.1%. The company's product has seen high-speed growth year-on-year for several consecutive quarters. From the fourth quarter of 2023 to the second quarter of 2024, the product revenue increased by over 65%, over 60%, and about 50% compared to the same period. At the same time, the company's sales scale effect is evident, with a decrease in multiple expense rates. In the first half of 2024, the gross margin was 84.1%, up 1.8 percentage points, and the sales and marketing expense ratio was 48.6%, down 5.9.
No Data
No Data